	•					SH	EET	10	F <u>1</u>
Substitute for forms 1449A/PTO & 1449B/PTO				ATTORNEY'S DKT NO. APPLI 032942-032 09/89			CATION NO. 2,636		
SECOND INFORMATION DISCLOSURE				APPLICANT Malcolm KING et al					
STATEMENT BY APPLICANT				FILING DATE GROU					
				June 28, 2001 1623					
0 5 2003									
U.S. PATENT DOCUMENTS									
DEMAENT Examiner Initials	Document Kind Code Name of Patentee or Applicant Number (if known) of Cited Document					Issue/Publication Date (MM-DD-YYYY)			
									-
						REC	E	VEI	<del>)</del>
	AUG 0 8 2003								
		1			TE	CH CEN	TER '	1600/2	2900
FOREIGN PATENT DOCUMENTS									
Examiner Initials	Document Number	Kind Code (if known)		Country			Date of Publication Translation (MM-DD-YYYY) Yes No		
W	0 988 041			EP		03-29-2000		Х	
· ,—				* · · · · · · · · · · · · · · · · · · ·		,			
NON PATENT LITERATURE DOCUMENTS									
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.								
J. J.	Wei Feng, et al, "Improved Clearability of Cystic Fibrosis Sputum with Dextran Treatment <i>in vitro</i> ," American Journal of Respiratory and Critical Care Medicine, Vol. 157, 1998, pp. 710-714.								
Mo	W. Feng, et al, "Improved Clearability of Cystic Fibrosis Spectrum with Dextran Treatment in vitro," Clin. Invest. Med., Vol. 20, No. 4 suppl., 1997, pp. S99.								
<u></u>									
Examiner	Date Jolean 2								
Signature	Julul			Considered	10/30/0	<u> フ</u>			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.